Active Rac1‐Mediated Bone Marrow Retention Enhances CD33 CAR ‐T Cell Efficacy Against CD33 + Leukemia Cells
The FASEB Journal · 30.04.2026 · 40 (8)
DOI: 10.1096/fj.202503832rr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 10.04.2026. Verfasst von Shangshang Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Ke…. Hauptthemen laut MEDLINE: rac1 GTP-Binding Protein, Sialic Acid Binding Ig-like Lectin 3, Bone Marrow, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Key Research and Development Program of China, MOST|National Natural Science Foundation of China (NSFC), CAMS Innovation Fund for Medical Sciences.
Abstract (Originalsprache)
The bone marrow (BM) niche serves as a critical protective environment for leukemia cells, particularly chemo‐resistant leukemia cells, and plays a central role in driving therapeutic resistance and disease relapse in acute myeloid leukemia (AML). This specialized microenvironment not only promotes leukemia cell survival, but also inhibits T cell infiltration, which serves as a major obstacle to the effectiveness of CAR‐T therapy in myeloid malignancies. To overcome this limitation, we targeted Rac1 GTPase, a central regulator of cytoskeletal dynamics that controls membrane protrusion and migration, by engineering primary human T cells and CD33 CAR‐T cells to express constitutively active Rac1 (Rac1V12). Our results demonstrated that active Rac1 enhanced the migration of T cells and CD33 CAR‐T cells and promoted their residence in the BM in vivo. Furthermore, CD33 CAR‐T cells expressing Rac1V12 displayed enhanced cytotoxicity against leukemia cells in vitro, as demonstrated by transwell migration‐dependent killing assays. Crucially, these engineered CAR‐T cells achieved superior robust suppression of leukemia in vivo and significantly prolonged survival in xenograft models. Mechanistically, Rac1V12 CD33 CAR‐T cells in the BM demonstrated enhanced immunological memory phenotype and lower tonic signaling, a combination that promotes T cell persistence and enhances anti‐tumor efficacy in vivo. Our data suggest that active Rac1‐engineered CD33 CAR‐T cells represent a novel strategy for targeting BM leukemia cells, with the potential to eradicate AML cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Institute of Hematolo…
- Tianjin Institutes of Health Science, Tianjin, China.
ORCID-Profile: Jianxiang Wang
Förderung
- National Key Research and Development Program of China
- MOST|National Natural Science Foundation of China (NSFC)
- CAMS Innovation Fund for Medical Sciences
- National Natural Science Foundation of China
Zitieren
APA
Wang, S., Li, L., Xing, H., Xu, Y., Yan, Z., Ma, H., Yu, H., Ding, F., Tang, K., Tian, Z., Qiu, S., Wang, Y., Wang, M., Rao, Q., Gu, R., & Wang, J. (2026). Active Rac1‐Mediated Bone Marrow Retention Enhances CD33 CAR ‐T Cell Efficacy Against CD33 + Leukemia Cells. The FASEB Journal, 40(8). https://doi.org/10.1096/fj.202503832rr
Vancouver
Wang S, Li L, Xing H, Xu Y, Yan Z, Ma H, et al. Active Rac1‐Mediated Bone Marrow Retention Enhances CD33 CAR ‐T Cell Efficacy Against CD33 + Leukemia Cells. The FASEB Journal. 2026;40(8). doi:10.1096/fj.202503832rr
BibTeX
@article{Wang2026,
author = {Wang, Shangshang and Li, Le and Xing, Haiyan and Xu, Yingxi and Yan, Zhifeng and Ma, Haotian and Yu, Heye and Ding, Fan and Tang, Kejing and Tian, Zheng and Qiu, Shaowei and Wang, Ying and Wang, Min and Rao, Qing and Gu, Runxia and Wang, Jianxiang},
title = {Active Rac1‐Mediated Bone Marrow Retention Enhances CD33 CAR ‐T Cell Efficacy Against CD33 + Leukemia Cells},
journal = {The FASEB Journal},
year = {2026},
volume = {40},
number = {8},
doi = {10.1096/fj.202503832rr}
}
EUVIMED